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ABSTRACT 
Crohn’s disease (CD) is a chronic, inflammatory illness of the digestive tract, characterized by 
alternating periods of remission and recurrence. The pathogenesis of CD is still unclear but probably is 
a result of a complex interaction between immunological, genetic and microbiological disorders. In 
recent years, there has been an increasing extent of evidence that gut microbiota plays a very 
important role in the pathogenesis of CD. Currently, the most effective treatment is biological therapy 
using anti-TNF monoclonal antibodies. It is interesting whether biological drugs resulting in fast 
remission, contributes to the normalization of the gut microbiota. Due to the fact that the children’s 
population is a significant percentage of all patients with CD, it is important to pay close attention to 
the problem of microbiological disorders in this age group. The aim of this study was to investigate 
whether there are quantitative changes of chosen bacteria species and fungi of the genus Candida in 
children with Crohn's disease relative to healthy children and assesment of quantitative changes in 
patients after biological treatment. In the group of children with Crohn’s disease, the numbers in 
Candida were significantly higher (9.74×10
17 
CFU/g) than in the control group (9.35×10
10
 CFU/g, p = 
0.011). Biological therapy led to a significant reduction in the amount Candida (5.91×10
11
) and was 
comparable with the number
 
in the control group
. 
In the case of bacteria, we observed an increase in S. 
marcescens (3,4×10
8
) in the patients group compared to the controls (1,85×10
8
) and an increase in L. 
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fermentum (2,34×10
10
) in relation to healthy children (3,31×10
8
, p = 0,048) Biological treatment had 
an impact on the decrease in L. fermentum (4,76×10
9
,
 
p = 0.05)  
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1.  INTRODUCTION 
 
Crohn’s disease (CD) is a chronic, inflammatory illness of the digestive tract, 
characterized by alternating periods of remission and recurrence. Symptoms of CD range 
from chronic, persistent diarrhea, nausea, abdominal pain and emesis to complications outside 
the gastrointestinal tract including arthritis, erythema nodosum, weight loss or delayed sexual 
maturation and growth in children [1].  
The pathogenesis of this disease is still unclear but it is probably a result of a complex 
interaction between immunological, genetic and microbiological disorders. In recent years, 
there has been an increasing extent of evidence that gut microbiota plays a very important role 
in the pathogenesis of CD [2-4]. The first investigations focused on involving individual 
pathogens which could participate in the initiation of inflammation of the digestive tract. In 
particular, the contribution of Mycobacterium paratuberculosis (MAP), Bacteroides fragilis 
and adherent-invasive Escherichia coli (AIEC) pathotype have been considered [5-7]. 
Although the above mentioned bacteria are often found in people with CD and have a 
predisposition to initiate inflammation, so far reliable evidence has not been found confirming 
the participation of a specific microorganism in promoting the disease. Recently, it has been 
suggested that CD may not be caused by pathogenic microorganism but rather by intestinal 
dysbiosis leading to the growth of proinflammatory microbial species which constantly 
stimulate the immune system and interfere with its action or it is the effect of abnormal 
immune response directed against commensal microbes colonizing the gastrointestinal tract 
[8]. 
Crohn’s disease is incurable so the aim of medical treatment is to reduce  
the inflammation which triggers the symptoms and which may lead to remission. The main 
drugs used in CD are 5-aminosalicylic acid (5-ASA) preparations and corticosteroids, but they 
are not always effective. In severe cases, the most effective treatment is biological therapy 
with anti-TNF antibodies, such as infliximab or adalimumab, which causes the healing of the 
inflammation of the intestinal mucosa [9].  
These agents bind to TNF-α with high affinity thereby neutralizing biological activity of 
this proinflammatory cytokine. It is interesting whether the biological treatment resulting in 
fast remission, contributes to the normalization of the gut microbiota and if it is similar to the 
intestinal flora in healthy people. Due to the fact that the children’s population accounts for a 
significant percentage of all patients with CD, it is important to pay close attention to the 
problem of microbiological disorders in this age group. Therefore, the aim of this study was 
to investigate whether there are any quantitative changes of chosen microorganisms in 
children with Crohn’s disease in relation healthy children and assessment of quantitative 
changes in patients after biological treatment. 
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2.  MATERIAL AND METHODS 
 
Patients and samples: The study included 14 children hospitalized in the Department of 
Pediatrics, Gastroenterology and Nutrition, University Hospital, Kraków, Poland; whose 
diagnoses were based on clinical data, endoscopy, radiology and histology. Disease activity 
was scored by the Pediatric Crohn’s Disease Activity Index (PCDAI) [10]. The control group 
consisted of 18 healthy volunteers. The subjects were required to be children up to 18 years 
old. Children who were taking probiotics or antibiotics in the 4 weeks before sampling were 
excluded. The subjects provided informed consent for participation in the study. The study 
was performed according to the Declaration of Helsinki, and was approved by the Bioethical 
Committee of the Jagiellonian University No. 122.6120.67.2015. 
The control and patients were asked to deliver stool samples. Children with CD 
provided their stool samples twice: before anti-TNF-α (Remsima®) biological treatment and 
2 weeks after the end of treatment which lasted 6 weeks. Samples were stored at -70 °C until 
analysis.  
 
Table 1. Characteristics of the studied population 
 
 
Children with CD 
n = 14 
Healthy children 
n = 18 
Girls 7 9 
Boys 7 9 
Age 
(± SD) 
13 
(± 4,51) 
11 
(± 3,45) 
 
 
DNA extraction and PCR amplification: Fecal bacterial and fungal DNA was 
extracted from 200-300 mg of feces. Isolation was carried out using Genomic mini AX Stool 
(A&A Biotechnology, Gdynia, Poland) along with pretreatment including enzymatic lysis 
with lysozyme (A&A Biotechnology), lysostaphin (A&A Biotechnology), lyticase (Sigma) 
and mechanical lysis using a FastPrep homogenizer (MP Biomedicals). Briefly, 100 µl NaCl, 
20 µl of lysozyme and 10 µl of lysostaphin were added into the tubes containing 200-300 mg 
of feces and glass beads.. The samples were homogenized (30 s, speed 4,0 m/s) using 
FastPrep and incubated for 30 min at 37 °C. Next, 200 μl NaOH (Sigma) was added and left 
for 10 min at 95 °C.  
After incubation, the tubes were cenrtifuged at 12 000 rpm for 10min (MPW-215 
Adverti, Lodz, Poland). The supernatant was discarded and 500 μl buffer with  
β-mercaptoethanol (A&A Biotechnology) and lyticase were added into the precipitate. The 
samples were incubated at 37 °C for 30 min. The consecutive steps of DNA isolation were 
performed according to the Genomic mini AX Stool protocol pursuant to the producer’s 
instructions.  
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The extracted DNA was quantitatively examined for the following selected CD 
microbiota constituents: Bacteroides fragilis, Lactobacillus fermentum, Lactobacillus 
rhamnosus, Serratia marcescens and Candida spp.. by quantitative Real Time Polymerase 
Chain Reaction (qPCR) using the BioRad CFX96 thermal cycler. The reaction was prepared 
in a volume of 10µl. The mixture used in qPCR in the case of bacteria contained: 2,8µl of 
water, 5,0 µl of Real Time PCR Mix SYBR® C reaction mixture (A&A Biotechnology),  
0,1 µl of forward primer (20 mM), 0,1 µl of reverse primer (20 mM) and 2 µl of DNA. 
TaqMan probe FAM-5′-TTAACCTACTAAATAGTGCTGCTAGC-BHQ1-3′ (Genomed) 
[14] was used to detect Candida DNA and the composition of the reaction mixture was as 
follows: 2 µl of water, 5,0 µl of Real Time PCR Mix Probe (A&A Biotechnology) reaction 
mixture, 0,2 µl of forward primer (20 mM), 0,2 µl of  reverse primer (20 mM) and probe  
(10 mM). The applied primers specific for the above-mentioned microorganisms are shown in 
Table 2. Oligonucleotides were synthesized by Genomed. The amplification programs are 
described in Table 3. Total microbial concentration was determined using standard curves 
which were generated from 10-fold serial dilutions of known concentrations of reference 
strain genomic bacterial or fungal DNA (range: 10
1
 – 10
7
). The number of selected 
microorganisms was calculated per gram of stool by interpolating the cycle threshold (Ct) 
values obtained from the samples relative to appropriate standard calibration curve. 
 
Table 2. Primers used in the qPCR reaction 
 
Microorganisms Primers Sequence 5’3’ 
Melting 
temperature 
(°C) 
References 
Bacteroides 
fragilis 
Forward 5′-TCRGGAAGAAAGCTTGCT-3′ 45,8 
[11] 
Reverse 5′-CATCCTTTACCGGAATCCT-3′ 48,9 
Lactobacillus 
rhamnosus 
 
Forward 5′-CGGCTGGATCACCTCCTTT-3′ 53,2 
[12] 
Reverse 5′-GCTTGAGGGTAATCCCCTCAA-3′ 54,4 
Serratia 
marcescens 
 
Forward 5’- TGCCTGGAAAGCGGCGATGG-3’ 57,9 
[13] 
Reverse 5’- CGCCAGCTCGTCGTTGTGGT-3’ 57,9 
Lactobacillus  
fermentum 
 
Forward 5’-AACCGAGACCACCGCGTTAT-3’ 51,8 
[14] 
Reverse 5’-ACTTAACCTTACTGATCGTAGATCAGTC-3’ 57,3 
Candida spp. 
 
Forward 5’-TTGGTGGAGTGATTTGTCTGCT-3’ 53 
[15] 
Reverse 5’-TCTAAGGGCATCACAGACCTG-3’ 54,4 
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To compare differences between the patients subjected to biological treatment the 
control group, as well as to check whether this difference is statistically significant, the non-
parametric Mann–Whitney U test was used. The value of p <0.05 was considered statistically 
significant. 
 
Table 3. Thermal profile of the qPCR reaction 
 
 
 
 
 
.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.  RESULTS 
 
In this study we quantified a selected microorganisms in stool samples taken from 
children with Crohn’s disease in relation to control group and for the first time we examined 
the influence of biological treatment on the intestinal microflora. The average bacterial and 
fungal quantifications of stool in each group are presented in Table 4. The comparisons of the 
fecal microorganisms in all groups is shown in Fig. 1. 
Bacteroides 
fragilis 
 
95 °C –  5 min 
95 °C –  30 sec 
45 °C – 30 sec 
  72 °C –  30 sec 
 
Lactobacillus 
fermentum 
 
95 °C –    5 min 
95 °C –    30 sec 
51 °C –    30 sec 
  72 °C –    30 sec 
 
Lactobacillus 
rhamnosus 
 
95 °C –    5 min 
95 °C –    30 sec 
52.4 °C – 30 sec 
  72 °C –    30 sec 
Serratia 
marcescens 
 
95 °C –    5 min 
95 °C –    20 sec 
55 °C –    30 sec 
  72 °C –    1 sec 
Candida spp. 
 
95 °C –    2 min 
95 °C –    15 sec 
55 °C –    30 sec 
  72 °C –    30 sec 
50 x 
40 x 
50 x 
50 x 
 
39 x 
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Fig. 1. Quantitative evaluation of bacteria detected in the feces of patients with CD before 
biological treatment, after treatment and control using qPCR.  
* significant differences between children with CD and the control group;  
#
 
 significant differences between children with CD before biological treatment and after therapy 
 
 
 
Fig. 2. Quantitative assessment of fungi of the genus Candida in the feces of patients with CD 
before biological treatment, after TNF-α therapy and control using qPCR. 
*significant differences between children with CD and the control group;  
# significant differences between children with CD before biological treatment and after therapy 
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We observed an increase in Candida in the group of children with Crohn’s disease. The 
number of fungal cell was a significantly higher compared to the control group (p=0.011). 
Moreover, biological therapies led to a substantial reduction in the number of fungi in the 
digestive tract of children with Crohn’s disease which were comparable with healthy control 
(p=1.0). In the case of bacteria, we observed an increase in S. marcescens in the patients 
group compared to the controls (p=0.048) and an increase in L. fermentum in relation to 
healthy children (p=0.001) Biological treatment had an impact on the decrease in L 
.fermentum (p=0.05) and caused reduction in number of S.marcescens but in this case, it was 
not statistically significant. There were no quantitative changes in L. rhamnosus among the 
patients relative to the healthy group. 
 
Table 4. Median number of microorganisms isolated per gram in the studied groups 
 
Microorganism 
Number of 
microorganisms in 
stool of children with 
CD before biological 
treatment [CFU/g] 
Number of 
microorganisms in 
stool of children with 
CD after biological 
treatment [CFU/g] 
Number of 
microorganisms in 
stool of children in 
the control group 
[CFU/g] 
Candida spp. 9.74×10
17a,b
 5.91×10
11
 9.40×10
10
 
Bacteroides fragilis 3.49×10
8
 1.68×10
7
 1.45×10
9
 
Lactobacillus 
fermentum 
2.34×10
10a,b
 4.76×10
9
 3.31×10
8
 
Lactobacillus 
rhamnosus 
9.25×10
7
 7.23×10
7
 2.46×10
8
 
Serratia marcescens 3.4×10
8a
 5.1×10
7
 1.85×10
8
 
a
 p<0.05 differences between children with CD and the control group; 
b 
p<0.05 differences between children with CD before biological treatment and after therapy 
 
 
4.  DISCUSSION 
 
4 types of bacteria consitute more than 90% of the natural gut microbiota: Firmicutes 
(64%), Bacteroidetes (24%), Proteobacteria (8%) and Actinobacteria (3%) among which the 
following types are predominant: Bifidobacterium, Lactobacillus, Streptococcus, 
Enterobacteriaceae and Bacteroides [16]. Their occurrence brings many positive aspects such 
as: neutralization of toxins, supporting digestive processes, sealing of the intestinal barrier  
or protection against pathogenic bacteria. Maintaining a balance between specific strains is a 
necessary condition for preserving homeostasis and appropriate functioning of the body. 
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Among the people suffering from CD, an imbalance can be found in the amount, 
composition and functioning of individual microorganisms, which is referred to as dysbiosis. 
Scientific data show that quantitative changes of gut microorganisms may cause excessive 
stimulation of the immune system - which in genetically predisposed people, results in 
autoimmune diseases, including CD [8]. 
One of the several bacteria widely suspected of pathogenesis of Crohn’s disease is 
Bacteroides fragilis. A lot of studies have shown a significant abundance of these bacteria in 
people with CD [17,18]. A potential virulence factor of B.fragilis is the production of 
enterotoxin - fragilysin, which hydrolyzes cadherin peptide bonds, a protein that is part of 
tight junctions. Disruption of the intestinal mucosa barrier by division of these intercellular 
proteins between enterocytes leads to an increase in intestinal permeability, which allows the 
passage of undesirable substances such as toxin, bacterial or food antigens from inside the 
gastrointestinal tract into the bloodstream, leading to the development of chronic 
inflammation [19]. In this study, we did not observe a significant abundance of this bacterium  
in stool samples of patients. Also, biological treatment did not affect the quantitative changes 
as regards this microorganism. A lot of studies confirming an increase in B.fragilis in CD 
patients were carried out with the participation of adults. Our studies in children did not show 
an increase in the number of these bacteria in a pediatric group with CD, which can suggest 
that quantitative abnormalities of Bacteroides which were found in the previous research, may 
be a secondary effect of the disease and be a result of a long-lasting inflammatory process of 
the digestive system, but they are not the primary cause of Crohn’s disease. 
A new subject for research in the pathogenesis of Crohn’s disease is S. marcescens. 
Until now, the only study taking into account the participation of this bacterium in the 
pathogenesis, carried out by Hourau et al. showed  a significant abundance of S.marcescens 
cells in patients with CD. Moreover, the researchers showed that the abundance of this 
bacterium was correlated with excessive numbers of Escherichia coli and Candida tropicalis. 
Interestingly, it was noted that these microorganisms cooperate together to form a thick layer 
of biofilm tightly adhering to the intestine, thus inducing an inflammatory reaction that could 
result in symptoms of Crohn’s disease [20]. In our study, we also observed statistically 
significant increased numbers of S.marcescens in patients. Moreover, we proved a significant 
abundance of Candida spp. in stool samples of children with Crohn’s disease. Interestingly, 
anti-TNF-α therapy had an impact on reducing the amount of fungal cells and after treatment 
they were comparable to healthy children. These results may suggest that among patients with 
CD there is a loss of tolerance towards commensal fungi residing in the digestive tract, which 
results in hyper-activity of the gastrointestinal tract with release excessive amounts 
of TNF-α, leading to non-specific intestinal tissue damage. With the reduction of 
inflammation and healing of the intestinal mucosa, the number of fungi is reduced and is 
similar to the one in healthy people. The confirmation of this hypothesis may be the results of 
study carried out by Iliev et al., which showed that mice with polymorphisms within the 
Dectin-1 receptor (involved in innate immune responses to fungal pathogens), do not tolerate 
intestinal fungi of the genus Candida and release excessive amounts of TNF-α and IFN-γ 
cytokines against them which results in inflammatory bowel disease [21]. When secretion of 
TNF-α is stopped after the administration of biological drugs, the number of Candida 
decreases and patients receive long-term remission even after the therapy. 
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There are varied reports about changes in the abundance of Lactobacillus in people with 
CD. Some studies have reported an increased number of Lactobacillus among patients [22] 
while others claim that there is a significantly reduced number of these bacteria [23].  
The strong interest of researchers in this bacterium is primarily due to the fact that the 
majority of Lactobacillus strains have a beneficial effect on the human body and are used as 
probiotic preparations which have a preventive effect against the invasion of pathogenic 
microorganisms and also have a soothing effect on diarrhea or abdominal pain. Therefore, 
some researchers assumed that in Crohn’s disease too low amounts of the individual strains of 
the genus Lactobacillus may be present resulting in a weakened protective barrier against 
pathogenic strains inducing an inflammatory response and manifested by frequent diarrhea. 
The best-documented health benefits are demonstrated by L. rhamnosus, which is commonly 
used in the form of probiotic preparations and has antidiarrheal properties and inhibitory 
effects on the growth of pathogenic bacteria [24, 25], therefore, we wanted to examine the 
amount of this strain in the patient population. In our study, there were no statistically 
significant differences in the colonization of the intestine by Lactobacillus rhamnosus in 
children compared to the healthy control.  
Biological treatment did not influence the amount of these microorganisms either. 
Considering the fact, that previous studies (which showed different results from ours) were 
carried out on adults whose disease processes have been ongoing for many years, it may be 
assumed that in older people with CD, quantitative changes within commensal bacteria are 
most likely caused by environmental factors such as long-term use of antibiotics like 
metronidazole or ciprofloxacin, which are often used as an auxiliary therapy of Crohn’s 
disease or may be the result of diet (poor in dairy products which are a source of 
Lactobacillus), hence decreased levels of these bacteria are caused by long-term influence of 
external factors and most probably, that the participation of L. rhamnosus does not play a 
direct role in the initiation and pathogenesis of this disease entity. In addition, this thesis can 
be confirmed by the fact that attempts at probiotic application of the bacteria from the genus 
Lactobacillus to people with Crohn’s disease do not contribute to relieving symptoms or 
inducing remission [26, 27]. It should be note that Lactobacillus is a huge group of bacteria, 
which includes many species with extremely different life requirements and various effects on 
the human body, so it can not be ruled out that the inflammatory process in the 
gastrointestinal tract in the course of CD, determines in some way the amount of certain 
species of lactobacilli. In our study, for the first time we examined the participation of  
L. fermentum in Crohn’s disease in people.  
One should pay attention to the fact that in stool samples of children with Crohn’s 
disease an increase in this strain was observed. Moreover, biological therapy led to reduced 
levels of L. fermentum. It must be noted that this species of Lactobacillus produces H2O2 and 
thereby may induce inflammation in the intestine, which would explain the increased number 
of these bacteria in patients [28, 29]. When the inflamed tissue is healing due to the biological 
treatment, the amount of bacteria is reduced. Moreover, previous studies on the potential risks 
associated with these probiotic bacteria - suggested that some strains of L. fermentum can 
have a negative influence on intestinal barrier integrity. Anderson et al. demonstrated that 
some human oral isolates of this microorganism caused an increased expression of genes and 
an abundance of proteins responsible for loosening the tight junction between epithelial cells 
[30] which is an important disorder in the pathogenesis of CD. Furthermore, other 
independent studies involving rats showed strong proinflammatory properties of a certain 
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strain of L .fermentum. Anderson et al. proved that this bacterium has an impact on the 
activity of the Toll - like receptor (TLR) belonging to pattern recognition receptors (PRRs). 
Due to TLR, the human immune system is able to distinguish non-self antigens from self-
antigens. Unexpectedly, L. fermentum, belonging to the commensal microflora, induced 
excessive expression of PRR, resulting in the release of a significant amount of 
proinflammatory cytokines such as TNF-alpha and IL-6 [31]. These data show that, among 
the patients with CD, there may be genetic disorders within the TLR resulting in an excessive 
immune response to the abundance of L. fermentum resulting in intestinal inflammation. 
Further studies are needed regarding the participation of this bacterium in the pathogenesis of 
CD. 
 
 
5.  CONCLUSION 
 
In the group of children with Crohn’s disease, the numbers of Candida, S. marcescens  
and L. fermentum were a significantly higher than in the control group. Biological therapy led 
to a significant reduction in the amount of the Candida fungi and L. fermentum in the stool 
sample from children with Crohn’s disease. Biological treatment did not impact the reduction 
in the number of S. marcescens. Differences in the numbers of B. fragilis or L. rhamnosus 
were not observed. 
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